JP2023549849A5 - - Google Patents

Info

Publication number
JP2023549849A5
JP2023549849A5 JP2023528620A JP2023528620A JP2023549849A5 JP 2023549849 A5 JP2023549849 A5 JP 2023549849A5 JP 2023528620 A JP2023528620 A JP 2023528620A JP 2023528620 A JP2023528620 A JP 2023528620A JP 2023549849 A5 JP2023549849 A5 JP 2023549849A5
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
angioedema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081493 external-priority patent/WO2022101395A1/en
Publication of JP2023549849A publication Critical patent/JP2023549849A/ja
Publication of JP2023549849A5 publication Critical patent/JP2023549849A5/ja
Pending legal-status Critical Current

Links

JP2023528620A 2020-11-12 2021-11-12 血管性浮腫の予防および処置 Pending JP2023549849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
EP20207273.2 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (2)

Publication Number Publication Date
JP2023549849A JP2023549849A (ja) 2023-11-29
JP2023549849A5 true JP2023549849A5 (cg-RX-API-DMAC7.html) 2024-11-18

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528620A Pending JP2023549849A (ja) 2020-11-12 2021-11-12 血管性浮腫の予防および処置

Country Status (13)

Country Link
US (1) US12629363B2 (cg-RX-API-DMAC7.html)
EP (1) EP4243824B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549849A (cg-RX-API-DMAC7.html)
KR (1) KR20230107269A (cg-RX-API-DMAC7.html)
CN (1) CN116685353A (cg-RX-API-DMAC7.html)
AU (1) AU2021376885A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198246A1 (cg-RX-API-DMAC7.html)
ES (1) ES3061585T3 (cg-RX-API-DMAC7.html)
IL (1) IL302887A (cg-RX-API-DMAC7.html)
MX (1) MX2023005563A (cg-RX-API-DMAC7.html)
PL (1) PL4243824T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022101395A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305122B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
HRP20260166T1 (hr) * 2022-03-25 2026-03-27 Pharvaris Gmbh Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora
EP4745196A1 (en) 2023-08-16 2026-05-20 LG Chem, Ltd. RESIN COMPOSITION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina

Similar Documents

Publication Publication Date Title
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP7548669B2 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
JP2023166406A5 (cg-RX-API-DMAC7.html)
CN107427502A (zh) 使用川地匹坦的治疗方法
JP2022511788A5 (cg-RX-API-DMAC7.html)
JP2023531675A5 (cg-RX-API-DMAC7.html)
JP2020500864A5 (cg-RX-API-DMAC7.html)
JP2024527023A5 (cg-RX-API-DMAC7.html)
JP2022533968A5 (cg-RX-API-DMAC7.html)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
Sticherling Systemic sclerosis–the dermatological perspective
US20230233506A1 (en) Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker
BRPI0716214A2 (pt) Composições farmacêuticas para o tratamento de infecções fúngicas.
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2022517902A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
JP2025509278A5 (cg-RX-API-DMAC7.html)
JP2019535830A5 (cg-RX-API-DMAC7.html)
CA2760176C (en) Use of benzydamine in the treatment of p40-dependent diseases
JP2025522146A5 (cg-RX-API-DMAC7.html)
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用